LEADPHARMA Trademark

Trademark Overview

On Wednesday, June 9, 2021, a trademark application was filed for LEADPHARMA with the United States Patent and Trademark Office. The USPTO has given the LEADPHARMA trademark a serial number of 79319025. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Wednesday, October 12, 2022. This trademark is owned by Lead Pharma Holding B.V.. The LEADPHARMA trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations and pharmaceutical products for the treatment and prevention of autoimmune diseases, cancer, metabolic diseases, cardiological diseases, haematological diseases, diabetes, urological diseases, eye diseases, osteoporosis, depression, mental illness, bone diseases, respiratory diseases, asthma, kidney diseases, gastrointestinal diseases
leadpharma

General Information

Serial Number79319025
Word MarkLEADPHARMA
Filing DateWednesday, June 9, 2021
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateWednesday, October 12, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and Servicespharmaceutical preparations and pharmaceutical products for the treatment and prevention of autoimmune diseases, cancer, metabolic diseases, cardiological diseases, haematological diseases, diabetes, urological diseases, eye diseases, osteoporosis, depression, mental illness, bone diseases, respiratory diseases, asthma, kidney diseases, gastrointestinal diseases
Pseudo MarkLEAD PHARMA

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, September 3, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameLead Pharma Holding B.V.
Party Type10 - Original Applicant
Legal Entity Type26 - NOT AVAILABLE
AddressNL

Trademark Events

Event DateEvent Description
Tuesday, October 31, 2023FINAL DECISION TRANSACTION PROCESSED BY IB
Friday, October 27, 2023LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Thursday, October 12, 2023FINAL DISPOSITION NOTICE SENT TO IB
Thursday, October 12, 2023FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Saturday, August 19, 2023LIMITATION OF GOODS RECEIVED FROM IB
Wednesday, April 12, 2023NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Wednesday, March 22, 2023NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, March 22, 2023NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Wednesday, October 12, 2022ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Wednesday, October 12, 2022ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Wednesday, October 12, 2022ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Monday, April 25, 2022REFUSAL PROCESSED BY IB
Friday, April 1, 2022NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Thursday, March 31, 2022REFUSAL PROCESSED BY MPU
Wednesday, March 2, 2022NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, March 1, 2022NON-FINAL ACTION WRITTEN
Monday, February 28, 2022ASSIGNED TO EXAMINER
Friday, November 12, 2021CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
Friday, October 29, 2021CORRECTION TRANSACTION RECEIVED FROM IB
Tuesday, September 7, 2021APPLICATION FILING RECEIPT MAILED
Friday, September 3, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, September 2, 2021LIMITATION FROM ORIGINAL APPLICATION ENTERED
Thursday, September 2, 2021SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

leadpharma diseases pharmaceutical illness mental depression osteoporosis bone gastrointestinal kidney asthma